Ameritas Investment Partners, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Ameritas Investment Partners, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 06, 2021	SELL	$92.19 - $115.71 $483,536 - $606,898	-5,245 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $5,024 - $7,883	-47 Reduced 0.89%	5,245 $597,000
Q4 2020 Feb 12, 2021	BUY	$84.4 - $177.39 $33,000 - $69,359	391 Added 7.98%	5,292 $733,000
Q3 2020 Nov 13, 2020	SELL	$72.98 - $90.0 $8,027 - $9,900	-110 Reduced 2.2%	4,901 $403,000
Q2 2020 Aug 05, 2020	BUY	$46.91 - $78.22 $7,364 - $12,280	157 Added 3.23%	5,011 $392,000

Q1 2020 May 13, 2020	BUY	$33.8 - $62.9 $7,030 - $13,083	208 Added 4.48%	4,854 $216,000
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $16,094 - $21,787	293 Added 6.73%	4,646 $295,000
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $15,947 - $27,744	400 Added 10.12%	4,353 $302,000
Q2 2018 Aug 13, 2018	BUY	$48.54 - $85.31 $9,271 - $16,294	191 Added 5.08%	3,953 $304,000
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $12,767 - $16,853	288 Added 8.29%	3,762 $192,000
Q2 2017 Aug 15, 2017	BUY	N/A	3,474	3,474 $216,000

286

78.6M

570K

228K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.87B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.